$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

성인형 스틸씨 병에서 병발된 비인두암의 치료 및 문헌 고찰
A Case Report and Literature Review : Treatment of Nasopharyngeal Cancer(NPC) Patient with AOSD(Adult Onset Still's Disease) 원문보기

대한 두경부 종양 학회지 = Korean journal of head & neck oncology, v.30 no.1, 2014년, pp.15 - 19  

김준영 (삼성창원병원 내과) ,  김진동 (삼성창원병원 내과) ,  이경빈 (삼성창원병원 내과) ,  이원재 (삼성창원병원 내과) ,  나건웅 (삼성창원병원 내과) ,  박원일 (삼성창원병원 내과) ,  박기철 (삼성창원병원 이비인후과) ,  김태규 (삼성창원병원 방사선종양학과) ,  지준호 (삼성창원병원 내과)

초록
AI-Helper 아이콘AI-Helper

비인두암에서 시행되는 방사선 치료 이후에 구강건조증과 피부 변화는 흔하게 볼 수 있는 합병증 중 하나이다. 비인두암의 좋은 예후를 고려할 때, 그러한 치료와 관련된 독성들은 상대적으로 오랫동안 문제를 야기하며 삶의 질 저하를 불러온다. 특히 류마티스 관절염, 루푸스와 같은 결합조직 질환을 가진 환자들에게서 방사선 치료를 시행하였을 때, 빈번하게 심각한 독성이 관찰된다. 본 증례는 성인형 스틸씨 병에서 병발된 비인두암의 치료로 항암방사선 동시치료를 실시한 결과, 비교적 경미한 구강 건조, 점막염, 불면증 등의 합병증이 관찰되었으나, 완전 관해가 획득되었다. 이에 저자들은 과거에 보고된 적 없는 성인형 스틸씨 병에 병발한 비인두암의 치료 경험을 다른 결합조직질환들에서 방사선 치료의 문헌들과 함께 보고하는 바이다.

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

제안 방법

  • In April, 2013, a 43-year-old women undergoing treatment with prednisolone for AOSD from 2008, presented with a 4- month history of progressive pain on left neck. She was diagnosed AOSD based on arthralgia with spiking fever and rash on both upper arm, thigh and face, with negative ANA and Rheumatic factor test at other tertiary hospital. She had been difficult at swallowing and 7 kg weight loss during 6 months, Upon physical examination, painless non-movable neck mass on left side was palpated.
  • She was treated with IMRT using 60Co γ-ray to an area extending from the nasopharynx to the lower cervicalarea through opposing lateral parapharyngeal area at a rate of 2.24 Gy/day(67.2 Gy/30 Fx).
  • The work-up included neck computed tomography(CT), magnetic resonance imaging(MRI) and 18-FDG-positron emission tomography(PET) scan that showed a well enhanced mass in the left rosenmullar fossa across midline with enlarged regional lymph nodes. The main mass extended longus coils, pterygoid muscle and clivus.
본문요약 정보가 도움이 되었나요?

참고문헌 (30)

  1. Afqir S, Ismaili N, Errihani H. Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: Current status. Journal of Cancer Research and Therapeutics. 2009;5:3-7. 

  2. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal Carcinoma. 2002; 13:1007-1015. 

  3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians. 2013;63:11-30. 

  4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011; 61:69-90. 

  5. Kim TH, Ko YH, Lee MA, Kim BS, Chung SR, Yoo IeR, et al. Treatment outcome of cisplatin-based concurrent chemoradiotherapy in the patients with locally advanced nasopharyngeal cancer. Cancer research and treatment: Official Journal of Korean Cancer Association. 2008;40:62-70. 

  6. Chu ST, Wu PH, Hou YY, Chang KP, Chi CC, Lee CC. Primary tumor volume of nasopharyngeal carcinoma: Significance for recurrence and survival. Journal of the Chinese Medical Association: JCMA. 2008,71:461-466. 

  7. Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: A meta-analysis of the phase III randomized trials. BMC Cancer. 2010;10:558. 

  8. Mayr NA, Riggs CE Jr, Saag KG, Wen BC, Pennington EC, Hussey DH. Mixed connective tissue disease and radiation toxicity. A case report. Cancer. 1997;79:612-618. 

  9. Chen A, Obedian E, Haffty B. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J. 2001;7(6):480- 491. 

  10. Teo P, Tai TH, Choy D. Nasophayngeal carcinoma with dermatomyositis. International Journal of Radiation oncology, Biology, Physics. 1989;16:471-474. 

  11. Varga J, Haustein UF, Creech RH, Dwyer JP, Jimenez SA. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA: The Journal of the American Medical Association. 1991;265:3292-3295. 

  12. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Common Terminology Criteria for Adverse Events(CTCAE). J Am Acad Dermatol. 2012;67:1025-1039. 

  13. Chen WC, Lai CH, Lee TF, Hung CH, Liu KC, Tsai MF, et al. Scintigraphic assessment of salivary function after intensitymodulated radiotherapy for head and neck cancer: Correlations with parotid dose and quality of life. Oral Oncology. 2013;49:42-48. 

  14. Hadley T, Song C, Wells L, Lehnhardt J, Rogers MW, Anderson J, et al. Does hyperbaric oxygen therapy have the potential to improve salivary gland function in irradiated head and neck cancer patients? Medical Gas Research. 2013;3:15. 

  15. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. Journal of clinical oncology: Official Journal of the American Society of Clinical Oncology. 1993;11:1124-1131. 

  16. Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM, et al. Post-radiation severe xerostomia relieved by pilocarpine: A prospective French cooperative study. Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology. 2000;55:233-239. 

  17. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. The New England Journal of Medicine. 1993;329:390-395. 

  18. Jha N, Harris J, Seikaly H, Jacobs JR, McEwan AJ, Robbins KT, et al. A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in headand-neck cancer(RTOG 0244). International Journal of Radiation Oncology, Biology, Physics. 2012;84:437-442. 

  19. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. Journal of the National Cancer In-- 19 - stitute. 2005;97:536-539. 

  20. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial.Journal of clinical oncology: Official Journal of the American Society of Clinical Oncology. 2002;20:2038-2044. 

  21. Abbasi F, Farhadi S, Esmaili M. Efficacy of Pilocarpine and Bromhexine in Improving Radiotherapy-induced Xerostomia. Journal of Dental Research, Dental Clinics, Dental Prospects. 2013;7:86-90. 

  22. Kakoei S, Haghdoost AA, Rad M, Mohammadalizadeh S, Pourdamghan N, Nakhaei M, et al. Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Archives of Iranian Medicine. 2012;15:214-218. 

  23. Kadar J, Petrovicz E. Adult-onset Still's disease. Best Practice & Research Clinical Rheumatology. 2004;18:663-676. 

  24. Neishi J, Tsukada Y, Maehara T, Ueki K, Maezawa A, Nojima Y. Adult Still's disease as a paraneoplastic manifestation of breast cancer. Scandinavian Journal of Rheumatology. 2000;29: 328-330. 

  25. Komano Y, Kubota T, Wakabayashi S, Ochi S, Nonomura Y, Hagiyama H, et al. A case of paraneoplastic syndrome mimicking adult-onset Still's disease. Modern rheumatology/the Japan Rheumatism Association. 2004;14:410-413. 

  26. Wong P, Tam LS. Lymphoma in a patient with adult onset Still's disease refractory to immunosuppressants. Hong Kong Bull Rheum Dis. 2009;9:58-60. 

  27. Sono H, Matsuo K, Miyazato H, Sakaguchi M, Matsuda M, Hamada K, et al. A case of adult-onset Still's disease complicated by non-Hodgkin's lymphoma. Lupus. 2000;9:468-470. 

  28. Nakagawa Y, Furusyo N, Taniai H, Henzan H, Tsuchihashi T, Hayashi J. Chronic myelogenous leukemia that occurred two years after the diagnosis of adult Still's disease. Internal Medicine. 2005;44:994-997. 

  29. Wu N, Li Q, Gu CX, Ahmed T, Yao XP. Paraneoplastic syndrome mimicking adult-onset Still's disease caused by advanced lung cancer: A case report. BMC Cancer. 2011;11:487. 

  30. Bosch-Barrera J, Montero A, Lopez-Picazo JM, Garcia-Foncillas J, Ferrer M, Yuste JR, et al. Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. Lung Cancer. 2009;64:124-126. 

저자의 다른 논문 :

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로